Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$18,115.81 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of C$7.45, for a total value of C$18,115.81.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, July 1st, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.13, for a total transaction of C$14,902.03.

Fennec Pharmaceuticals Stock Performance

TSE:FRX opened at C$7.14 on Friday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a market cap of C$195.35 million, a PE ratio of 79.33 and a beta of 0.26. The firm has a 50 day simple moving average of C$8.19 and a 200-day simple moving average of C$10.64. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.00 and a 1-year high of C$15.43.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The business had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. On average, equities analysts expect that Fennec Pharmaceuticals Inc. will post 0.6058577 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.